Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-3: Weekly eloralintide in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity
CTR20262449Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of eloralintide in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity, Overweight, sponsored by Eli Lilly and Company. Started Jul 2026; status: active.
02
Drugs
eloralintide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesityOverweight
Beyond the preview
Go deeper on CTR20262449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262449.